FDA Inspection 1180544 — MORPHOSYS US INC
The FDA completed an inspection of MORPHOSYS US INC on Sep 16, 2022 in Boston, MA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Sep 16, 2022
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Boston, MA (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)